Published Date: 26 Apr 2023
According to a recent study from The University of Toledo, even at levels that are currently recognized, early exposure to the common class of insecticides known as pyrethroids may increase the risk of autism and other developmental disorders.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.
At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.
Fibromyalgia in 2025: Year in Review
Rheumatoid Arthritis in 2025: Year in Review
Asthma in 2025: Year in Review
C3 Glomerulopathy in 2025: Year in Review
1.
UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms
2.
A new theranostic drug targets different cancer types.
3.
For the first time in humans, a chemotherapy drug reaches the brain.
4.
Cardiomyocytes are shielded from chemotherapy damage by mitochondrial proteins.
5.
CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma
1.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
2.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
3.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
4.
Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology
5.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XI
3.
Efficient Management of First line ALK-rearranged NSCLC - Part II
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation